TY  - CHAP
M1  - Book, Section
TI  - Chapter 62. Perioperative Management of Patients Who Are Receiving Antiplatelet Therapy
A1  - Donadini, Marco Paolo
A1  - Douketis, James D.
A2  - McKean, Sylvia C.
A2  - Ross, John J.
A2  - Dressler, Daniel D.
A2  - Brotman, Daniel J.
A2  - Ginsberg, Jeffrey S.
Y1  - 2012
N1  - 
T2  - Principles and Practice of Hospital Medicine
AB  - The  perioperative  management  of  patients  who  are  receiving  antiplatelet  therapy  is  a  common  clinical  problem  given  the  large  number  of  patients  who  are  receiving  these  agents  for  treatment  of  coronary  artery  disease,  cerebrovascular  disease  or  peripheral  arterial  disease.  Such  patients  may  be  receiving:  acetylsalicylic  acid  (ASA)  alone;  clopidogrel  alone;  ASA  and  clopidogrel.  Patients  who  are  receiving  antiplatelet  drugs  encompass  a  broad  risk  spectrum  for  cardiovascular  events  that  depends  on  the  clinical  indication  for  antiplatelet  therapy  and  whether  patients  are  receiving  treatment  for  the  primary  or  secondary  prevention  of  cardiovascular  disease.  There  are  no  perioperative  risk  classification  schemes  that  consider  the  benefits  and  risks  of  continuing  or  interrupting  antiplatelet  therapy.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56195481
ER  -